Skip to main content
Midas Edge

Prelude Therapeutics Inc

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

PRLD$3.76+4.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Statements of Changes in Stockholders’ Equity (Unaudited)

STATEMENTS OF CHANGES INSTOCKHOLDERS’ EQUITY

Voting common stock · Non-voting commonstock · Additional paid-in · Accumulated other comprehensive · Accumulated
(in thousands, except shares) · Shares · Amount · Shares · Amount · capital · income (loss) · deficit · Total
Balance at January 1, 202542,298,859$412,850,259$1$714,982$35$(583,563)$131,459
Issuance of common stock upon vesting of RSUs, net of 3,859 shares withheld for employee taxes5,516———(5)——(5)
Issuance of common stock upon exercise of prefunded warrants1,299,827———————
Unrealized loss on marketable securities, net of tax—————(23)—(23)
Stock-based compensation expense————3,832——3,832
Net loss——————(32,085)(32,085)
Balance at March 31, 202543,604,202$412,850,259$1$718,809$12$(615,648)$103,178
Issuance of common stock upon exercise of stock options & vesting of RSUs, net of 3,355 shares withheld for employee taxes6,020———(2)——(2)
Issuance of common stock under ESPP133,844———92——92
Unrealized loss on marketable securities, net of tax—————(13)—(13)
Stock-based compensation expense————3,814——3,814
Net loss—————(31,231)(31,231)
Balance at June 30, 202543,744,066$412,850,259$1$722,713$(1)$(646,879)$75,838
Issuance of common stock upon exercise of stock options & vesting of RSUs, net of 3,355 shares withheld for employee taxes6,020———(5)——(5)
Unrealized gain on marketable securities————3—3
Stock-based compensation expense————2,423——2,423
Net loss—————(19,725)(19,725)
Balance at September 30, 202543,750,086$412,850,259$1$725,131$2$(666,604)$58,534

STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (CONTINUED)

Voting common stock · Non-voting common stock · Additional paid-in · Accumulated other comprehensive · Accumulated
(in thousands, except shares)SharesAmountSharesAmountcapitalincome (loss)deficitTotal
Balance at January 1, 202442,063,995$412,850,259$1$693,252$223$(456,390)$237,090
Issuance of common stock upon exercise of stock options & vesting of RSUs, net of 4,285 shares withheld for employee taxes7,510———(14)——(14)
Unrealized loss on marketable securities, net of tax—————(458)—(458)
Stock-based compensation expense————5,547——5,547
Net loss——————(31,431)(31,431)
Balance at March 31, 202442,071,505$412,850,259$1$698,785$(235)$(487,821)$210,734
Issuance of common stock upon exercise of stock options & vesting of RSUs, net of 3,722 shares withheld for employee taxes7,803———(16)——(16)
Issuance of common stock under ESPP78,916———255——255
Unrealized loss on marketable securities, net of tax—————(55)—(55)
Stock-based compensation expense————6,098——6,098
Net loss——————(34,740)(34,740)
Balance at June 30, 202442,158,224$412,850,259$1$705,122$(290)$(522,561)$182,276
Issuance of common stock upon exercise of stock options & vesting of RSUs, net of 3,722 shares withheld for employee taxes19,788———43——43
Unrealized gain on marketable securities—————457—457
Stock-based compensation expense, net of forfeitures of restricted stock awards————5,926——5,926
Net loss——————(32,271)(32,271)
Balance at September 30, 202442,178,012$412,850,259$1$711,091$167$(554,832)$156,431
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.